Cojutti, Pier Giorgio
Londero, Angela
Della Siega, Paola
Givone, Filippo
Fabris, Martina
Biasizzo, Jessica
Tascini, Carlo
Pea, Federico http://orcid.org/0000-0002-6966-7167
Funding for this research was provided by:
Università degli Studi di Udine
Article History
First Online: 27 August 2020
Declarations
:
: Open access funding provided by Università degli Studi di Udine within the CRUI-CARE Agreement. This research received no external funding.
: F.P. participated in speaker bureau for Angelini, Basilea Pharmaceutica, Gilead, Hikma, Merck Sharp & Dohme, Nordic Pharma, Pfizer and Sanofi Aventis, and in advisory board for Angelini, Basilea Pharmaceutica, Correvio, Gilead, Hikma, Merck Sharp & Dohme, Nordic Pharma, Novartis, Pfizer, Shionogi and Thermo-Fisher. A.L. participated in speaker bureau for Viiv, Gilead, Merck Sharp & Dohme and Janssen. C.T. participated in speaker bureau and received unconditional grants from Angelini, Biomerieux, Biotest, Gilead, Correvio, Hikma, Merck Sharp & Dohme, Pfizer, Shionogi, Thermo-Fisher, and Nordic Pharma. All other authors have no conflict of interest.
: The study was approved by the Regional Ethics Committee of Friuli Venezia Giulia Region, Italy.
: In light of the retrospective nature of the study, informed written consent was waived, according to the institutional policies for studies with a retrospective design.
: In light of the retrospective nature of the study, informed written consent was waived, according to the institutional policies for studies with a retrospective design.
: Not applicable.
: Not applicable.
: PGC and FP conceptualized the study, performed the analysis and drafted the manuscript; AL, PDS and FG acquired and interpreted clinical data; MF and JB performed the laboratory analysis; FP and CT supervised the project and reviewed the entire contents of the manuscript. All authors have read and agree to the published version of the manuscript.